Pharming Group N.V [PHAR] vs Recursion [RXRX] Detailed Stock Comparison
Pharming Group N.V
NASDAQ
Loading...
Recursion
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Pharming Group N.V wins in 11 metrics, Recursion wins in 6 metrics, with 0 ties. Pharming Group N.V appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pharming Group N.V | Recursion | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 69.31 | -2.69 | Recursion |
| Price-to-Book Ratio | 38.60 | 2.14 | Recursion |
| Debt-to-Equity Ratio | 53.57 | 9.58 | Recursion |
| PEG Ratio | N/A | -1.07 | N/A |
| EV/EBITDA | 386.44 | -2.74 | Recursion |
| Profit Margin (TTM) | -2.41% | 22.65% | Recursion |
| Operating Margin (TTM) | 3.27% | -916.75% | Pharming Group N.V |
| EBITDA Margin (TTM) | 3.27% | N/A | N/A |
| Return on Equity | -3.70% | -86.34% | Pharming Group N.V |
| Return on Assets (TTM) | 2.85% | -39.08% | Pharming Group N.V |
| Free Cash Flow (TTM) | $-2.59M | $-376.22M | Pharming Group N.V |
| 1-Year Return | 95.73% | -26.48% | Pharming Group N.V |
| Price-to-Sales Ratio (TTM) | 2.72 | 30.68 | Pharming Group N.V |
| Enterprise Value | $10.19B | $1.61B | Pharming Group N.V |
| EV/Revenue Ratio | 29.99 | 24.86 | Recursion |
| Gross Profit Margin (TTM) | 90.38% | -5.54% | Pharming Group N.V |
| Revenue per Share (TTM) | $5 | $0 | Pharming Group N.V |
| Earnings per Share (Diluted) | $-0.14 | $-1.81 | Pharming Group N.V |
| Beta (Stock Volatility) | 0.59 | 0.91 | Pharming Group N.V |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Pharming Group N.V vs Recursion Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pharming Group N.V | -0.81% | -3.80% | 29.91% | 26.99% | 89.66% | 40.34% |
| Recursion | -0.41% | 4.77% | -10.72% | -6.58% | -21.72% | -33.01% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pharming Group N.V | 95.73% | 31.54% | -5.84% | -5.84% | -5.84% | -5.84% |
| Recursion | -26.48% | -55.28% | -84.57% | -84.57% | -84.57% | -84.57% |
News Based Sentiment: Pharming Group N.V vs Recursion
Pharming Group N.V
News based Sentiment: POSITIVE
Pharming Group delivered strong Q2 results, raised guidance, and continues to attract institutional investment. While recent trading has shown some volatility, the overall narrative is positive, driven by revenue growth and a positive analyst outlook. The appointment of a new CFO adds another layer to the story.
Recursion
News based Sentiment: MIXED
Recursion showcased strong revenue growth in Q2 and continued to build strategic partnerships, but also reported significant losses and experienced notable insider selling. The mixed signals create a complex investment picture, requiring investors to weigh the potential for innovation against financial risks.
Performance & Financial Health Analysis: Pharming Group N.V vs Recursion
| Metric | PHAR | RXRX |
|---|---|---|
| Market Information | ||
| Market Cap | $953.47M | $1.98B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 9,864 | 13,730,077 |
| 90 Day Avg. Volume | 12,955 | 17,011,879 |
| Last Close | $14.68 | $4.83 |
| 52 Week Range | $7.10 - $17.08 | $3.79 - $12.36 |
| % from 52W High | -14.05% | -60.92% |
| All-Time High | $21.99 (Dec 21, 2020) | $42.81 (Jul 12, 2021) |
| % from All-Time High | -33.24% | -88.72% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.26% | 0.33% |
| Quarterly Earnings Growth | 0.26% | 0.33% |
| Financial Health | ||
| Profit Margin (TTM) | -0.02% | 0.23% |
| Operating Margin (TTM) | 0.03% | -9.17% |
| Return on Equity (TTM) | -0.04% | -0.86% |
| Debt to Equity (MRQ) | 53.57 | 9.58 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.35 | $2.12 |
| Cash per Share (MRQ) | $0.18 | $1.21 |
| Operating Cash Flow (TTM) | $31.05M | $-383,030,016 |
| Levered Free Cash Flow (TTM) | $23.18M | $-186,021,744 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Pharming Group N.V vs Recursion
| Metric | PHAR | RXRX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 69.31 | -2.69 |
| Forward P/E | 293.70 | -2.62 |
| PEG Ratio | N/A | -1.07 |
| Price to Sales (TTM) | 2.72 | 30.68 |
| Price to Book (MRQ) | 38.60 | 2.14 |
| Market Capitalization | ||
| Market Capitalization | $953.47M | $1.98B |
| Enterprise Value | $10.19B | $1.61B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 29.99 | 24.86 |
| Enterprise to EBITDA | 386.44 | -2.74 |
| Risk & Other Metrics | ||
| Beta | 0.59 | 0.91 |
| Book Value per Share (MRQ) | $0.35 | $2.12 |
Financial Statements Comparison: Pharming Group N.V vs Recursion
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PHAR | RXRX |
|---|---|---|
| Revenue/Sales | $93.22M | $19.10M |
| Cost of Goods Sold | $8.97M | $20.16M |
| Gross Profit | $84.25M | $-1.06M |
| Research & Development | $23.70M | $128.64M |
| Operating Income (EBIT) | $9.00M | $-176.23M |
| EBITDA | $9.79M | $-147.57M |
| Pre-Tax Income | $7.08M | $-171.90M |
| Income Tax | $2.53M | $0 |
| Net Income (Profit) | $4.55M | $-171.90M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PHAR | RXRX |
|---|---|---|
| Cash & Equivalents | $60.09M | $500.45M |
| Total Current Assets | $214.11M | $584.15M |
| Total Current Liabilities | $77.54M | $141.98M |
| Long-Term Debt | $110.36M | $72.47M |
| Total Shareholders Equity | $215.29M | $933.95M |
| Retained Earnings | $-292.80M | $-1.63B |
| Property, Plant & Equipment | $24.23M | $204.78M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PHAR | RXRX |
|---|---|---|
| Operating Cash Flow | $2.07M | $-143.55M |
| Capital Expenditures | N/A | $-1.83M |
| Free Cash Flow | $-56,000 | $-133.79M |
| Debt Repayment | $-715,000 | $-2.05M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PHAR | RXRX |
|---|---|---|
| Shares Short | 1,414 | 122.22M |
| Short Ratio | 0.14 | 4.63 |
| Short % of Float | 0.00% | 0.30% |
| Average Daily Volume (10 Day) | 9,864 | 13,730,077 |
| Average Daily Volume (90 Day) | 12,955 | 17,011,879 |
| Shares Outstanding | 680.31M | 396.51M |
| Float Shares | 670.71M | 416.22M |
| % Held by Insiders | 0.00% | 0.05% |
| % Held by Institutions | 0.00% | 0.69% |
Dividend Analysis & Yield Comparison: Pharming Group N.V vs Recursion
| Metric | PHAR | RXRX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |